Valuation: AstraZeneca PLC

Market Cap 251B 224B 208B 189B 356B 23,761B 363B 2,500B 978B 12,398B 941B 922B 39,671B P/E 2026 *
21.1x
P/E 2027 * 18.2x
Enterprise Value 271B 242B 225B 204B 384B 25,650B 391B 2,699B 1,056B 13,383B 1,016B 995B 42,825B EV / Sales 2026 *
4.27x
EV / Sales 2027 * 3.91x
Free-Float
96.62%
Yield 2026 *
2.07%
Yield 2027 * 2.19%
1 day+2.85%
Current month+79.64%
Current year+81.28%
Current year 89.04
Extreme 89.04
169.81
1 year 80.48
Extreme 80.48
169.81
3 years 60.47
Extreme 60.47
169.81
5 years 52.65
Extreme 52.65
169.81
10 years 25.55
Extreme 25.55
169.81
Manager TitleAgeSince
Chief Executive Officer 66 30/09/2012
Director of Finance/CFO 52 31/07/2021
Chief Operating Officer 55 31/05/2015
Director TitleAgeSince
Director/Board Member 70 05/04/1999
Director/Board Member 66 30/09/2012
Director/Board Member 65 26/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+2.88%+1.19% - - 251B
+2.81%+7.24%+51.74%+103.40% 1,077B
+1.12%-1.09%+32.70%+61.04% 612B
+0.40%+3.95%+25.18%+92.34% 501B
-0.93%+2.28%+73.13%+39.83% 364B
+2.37%+7.66%+33.65%+50.58% 353B
+2.64%+6.95%+21.01%+44.38% 278B
+3.24%+4.25%-0.31%+15.71% 251B
+2.65%+6.51%+45.96%+51.27% 230B
+2.56%+6.99%+33.03%+98.71% 190B
Average +1.91%+1.97%+35.12%+61.92% 428.5B
Weighted average by Cap. +1.85%+1.58%+38.76%+71.11%

Financials

2026 *2027 *
Net sales 63.4B 56.59B 52.6B 47.84B 90.01B 6,005B 91.63B 632B 247B 3,133B 238B 233B 10,026B 67.37B 60.13B 55.89B 50.84B 95.64B 6,381B 97.37B 671B 263B 3,329B 253B 247B 10,653B
Net income 11.81B 10.54B 9.79B 8.91B 16.76B 1,118B 17.06B 118B 46.03B 583B 44.3B 43.36B 1,867B 13.73B 12.25B 11.39B 10.36B 19.49B 1,300B 19.84B 137B 53.53B 678B 51.52B 50.43B 2,171B
Net Debt 19.94B 17.8B 16.54B 15.05B 28.31B 1,889B 28.82B 199B 77.75B 985B 74.83B 73.25B 3,153B 12.31B 10.98B 10.21B 9.29B 17.47B 1,165B 17.78B 123B 47.98B 608B 46.18B 45.2B 1,946B
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
15/10/26 US$166.67 +2.86% 3,910,474
14/10/26 US$162.03 +3.99% 3,333,925
13/10/26 US$155.82 -1.59% 3,112,422
12/10/26 US$158.33 -0.55% 2,855,694
09/10/26 US$159.20 +0.26% 2,121,775
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
161.75USD
Average target price
208.95USD
Spread / Average Target
+29.18%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AstraZeneca PLC